SOURCE: IBC Life Sciences

September 13, 2007 10:00 ET

IBC'S Anti-angiogenesis Conference to Feature Eight Academic Keynote Presentations

WESTBOROUGH, MA--(Marketwire - September 13, 2007) - IBC announced today that its upcoming Anti-angiogenesis conference will feature eight academic keynote presentations. Anti-angiogenesis will be held November 12-13, 2007 at the Courtyard Boston Tremont Hotel in Boston, MA.

Keynote presentations include:


--  Anti-angiogenic Therapy in Combination with Radiotherapy: From Bench
    to Bedside and Back
    Kevin Camphausen, M.D., National Cancer Institute
--  The Role of Circulating Endothelial and Progenitor Cells in Cancer
    Dan G. Duda, DMD, Ph.D., Massachusetts General Hospital
--  The Anti-angiogenesis Activity of Axon Guidance Mediators
    Michael Klagsbrun, Ph.D., Harvard Medical School/Children's Hospital,
    Boston
--  Drug Delivery Systems for Angiogenesis Inhibitors and Other
    Biomolecules
    Robert S. Langer, Sc.D., Massachusetts Institute of Technology
--  Mining the Urinary Proteome: Cancer Biomarker Discovery
    Marsha A. Moses, Ph.D., Harvard Medical School/Children's Hospital,
    Boston
--  Selective Inhibition of Pathologic Angiogenesis in Atherosclerosis
    Karen S. Moulton, M.D., Harvard Medical School/Children's Hospital,
    Boston
--  Integration of Anti-angiogenic Therapy with Radiation Therapy and
    other Modalities
    Michael S. O'Reilly, M.D., The University of Texas M. D. Anderson
    Cancer Center
--  Integrin a4B1 Activation During Bone Marrow Derived Cell Trafficking
    Promotes Tumor Neovascularization and Growth
    Michael C. Schmid, Ph.D., University of California San Diego
    


Michael C. Schmid, Ph.D., University of California San Diego

The Anti-angiogenesis conference is aimed to update attendees on new drugs and to better describe what makes an efficacious anti-angiogenic drug. The conference will also cover how anti-angiogenic drugs fit into the realm of anti-vascular modalities, understand why and what it takes to improve anti-angiogenic drug activity through combination strategies and appropriate drug delivery, and to learn how to follow activity of anti-angiogenic drugs through measurement and validity of biomarkers.

For questions about the Anti-angiogenesis Conference, contact IBC at 800.390.4078 or visit the conference website at http://www.IBCLifeSciences.com/Antiangio.

Writers and editors are encouraged to attend. To request a press pass please contact Sarah Hershberger at shershberger@ibcusa.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. For more information, visit www.IBCLifeSciences.com

Contact Information